Zobrazeno 1 - 10
of 191
pro vyhledávání: ''
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Weiwei Jin, Lianpeng Chang, Song Ye, Jiahong Jiang, Huaixiang Zhou, Yaping Xu, Liu Yang, Xiaoge Hu, Chao Ni
Publikováno v:
Molecular Cancer Therapeutics. 19:956-965
With the increase of treatment course, resistance to EGFR blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this resistance; however, the potential function of ot
Autor:
Michael J. Schell, Michael Nebozhyn, W. Jack Pledger, Jiannong Li, Jamie K. Teer, Mingli Yang, Timothy J. Yeatman, Andrey Loboda
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:1141-1152
Background: EGFR is a major therapeutic target for colorectal cancer. Currently, extended RAS/RAF testing identifies only nonresponders to EGFR inhibitors (EGFRi). We aimed to develop a mutation signature that further refines drug-sensitive subpopula
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Amit Aggarwal, Gregory P. Donoho, Gregory D. Plowman, Ramon V. Tiu, Robert D. Van Horn, Sheng Bin Peng, Youyan Zhang, Jason C. Ting, Ruslan D. Novosiadly, Yue Webster, Yung Mae M. Yao, Amelie Forest, Philip W. Iversen, Henry James Robert, Philip J. Ebert, Steven M. Bray
Publikováno v:
Clinical Cancer Research. 23:5547-5560
Purpose: To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models. Experimental Design: Seventy-nine well-characterized
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of
Autor:
Helmout Modjtahedi, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Said Abdullah Khelwatty
Publikováno v:
Cancer Research. 81:350-350
Background: Overexpression of the EGFR is common in patients with a wide range of cancers and the EGFR is an important target for therapy with monoclonal antibodies (mAbs) based drugs. Of these, cetuximab and panitumumab have been approved for the tr